-
Germany's dry rivers spark battle on engineering vs restoration
-
Putin visits Kuril islands claimed by Japan
-
Senators demand inquiry into conditions aboard USS Abraham Lincoln
-
Swiatek downs Svitolina to reach first WTA final of 2026
-
All Blacks' Proctor out of South Africa series, Mo'unga called up
-
Jones says Japan 'watching videos of geese' for Australia clash
-
Bangladesh quick Hasan reduces Australia to 74-4 at lunch
-
Bloodied but unbowed, defending champ Shelton reaches Montreal final
-
Seoul tech leads Asian stock gains as traders cheer US inflation
-
Wallabies make eight changes for return Japan Test
-
Farage and Count Binface go head-to-head in snap UK poll
-
Messi returns after father's death but Miami knocked out of Leagues Cup
-
Afghan students divided over smartphone ban at universities
-
Outflanked by AI, stars fade for South Korea's blind fortune-tellers
-
Japan go back to school for second Australia Test
-
Venezuela govt, opposition wrap up round of post-Maduro talks
-
Matthew McConaughey on his sweet return to the big screen
-
Five things to know about Zambia as it goes to the polls
-
President's economic record on the line as Zambia votes
-
Nakashima holds off Jodar to book first ATP Masters final in Montreal
-
Grieving Messi available for Miami in Leagues Cup clash
-
Trump 'low-key' bets on economic pressure against Iran
-
Colombia enters 'final phase' of quake search as toll hits 265
-
Pitch invaders take selfies with Fernandes during Man Utd friendly
-
Father-figure Christie helps guide Kounta to European silver
-
No-stress Sabalenka won't fret over lackluster 2026 results
-
McIlroy returns to St. Jude to launch marathon PGA playoff push
-
Hometown hero Hudson-Smith basks in Euro glory
-
Guimaraes makes Arsenal debut in Como friendly
-
PSG down Aston Villa to retain UEFA Super Cup
-
Travis Kelce says wedding to Taylor Swift was 'best night of my life'
-
Trump's spokesperson Karoline Leavitt to step down
-
US stocks mostly up after data shows slightly lower inflation in July
-
'Imposing ignorance': US climate science under siege
-
Caracas protest denounces secrecy of Venezuela transition talks
-
As millions gazed in awe, a swathe of Spain plunged into darkness
-
Hudson-Smith regains Euro 400m title on home track
-
Xavi named first foreign Netherlands coach since 1978
-
Rob Reiner son denies grand jury murder charges
-
NBA triple-double king Westbrook to retire after 18 seasons
-
Spain darkens as solar eclipses races south from Arctic
-
'Trying to bury the science': US climate research under siege
-
Skies darken as solar eclipse heads south from Arctic to Spain
-
Eurovision to bar countries at war from hosting
-
Protest denounces secrecy of Venezuela transition talks
-
Italian teenager Curtis breaks 50m backstroke world record at Europeans
-
NBA's Los Angeles Lakers to be sold for reported $12.5 bn
-
New mum Sjostrom wins 50m butterfly for 18th European gold
-
Lukaku joins Turkish side Fenerbahce from Napoli
-
Solar eclipse darkens Arctic Russia on course for Spain
Bayer sets aside more cash to deal with weedkiller woes
German pharmaceutical and agricultural chemicals giant Bayer said it had put aside an extra 1.2 billion euros ($1.4 billion) to deal with long-running US legal woes linked to a weedkiller.
It takes to 1.7 billion euros the amount set aside to deal with litigation linked to the glyphosate-based Roundup weedkiller, the German group said in a statement late Thursday.
Bayer also said it had achieved a "major settlement" with a law firm "reducing the total number of unresolved glyphosate claims to 61,000".
This means that a total of 131,000 claims had so far either been settled or deemed not eligible, it said.
The flood of legal cases in the United States relates to claims that the weedkiller causes blood cancer. Bayer says scientific studies and regulatory approvals show that the weedkiller is safe.
The Leverkusen-based group has already spent over $10 billion to settle cases.
Despite the extra provision for the legal cases, Bayer hiked its forecasts for 2025 due to a better-than-expected performance in its pharmaceuticals division.
The maker of Aspirin now expects sales of 46 to 48 billion euros this year up from a previous forecast of 45 to 47 billion.
It also predicted earnings before interest, taxes, depreciation and amortisation -- a key measure of profitability -- of 9.7 to 10.2 billion euros up from a previous forecast of 9.5 to 10 billion.
Its shares were up two percent on the blue-chip DAX index in Frankfurt Friday, while the broader index slipped 1.8 percent.
X.Brito--PC